Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OXS-4235
- Development stage
- Unknown
- Lead developer
- GT Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OXS-4235 is a small molecule therapeutic candidate developed as a chemical inhibitor of the P62-ZZ domain, targeting the treatment of multiple myeloma and associated osteolytic lesions. It is intended to selectively kill multiple myeloma cells while sparing healthy cells, potentially shrinking tumors and increasing bone density. The drug has shown preclinical activity in vitro and in vivo, demonstrating the ability to kill myeloma cells and decrease osteolytic bone lesions. It was developed by Dr. Sean Xie and is under development by Oxis Biotech, a subsidiary of GT Biopharma (formerly Oxis International)[1][2][3][4][5][6][7][9][13][14].
- Other names
- Oxis-4235Oxis4235Oxis 4235
02
Targets
SQSTM1 (Sequestosome-1)
Beyond the preview
Go deeper on OXS-4235.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OXS-4235.